文献速递脊柱关节炎

新ASDAS命名法与中轴型脊柱关节炎治疗决策的一致性

Is the new ASDAS nomenclature in agreement with therapeutic decision making in patients with axial spondyloarthritis?
PubMed 文献 · Semin Arthritis Rheum · 2020-07-23

该回顾性纵向研究纳入104例接受肿瘤坏死因子抑制剂首治的中轴型脊柱关节炎患者,共分析304次访视。结果显示,ASDAS低活动度时医生98.2%不升级治疗,高活动度时33.7%升级,很高活动度时82.8%升级,支持新ASDAS命名法。

要点

  • ASDAS低活动度时医生98.2%选择不升级治疗。
  • ASDAS高活动度时仅33.7%升级治疗,很高活动度时82.8%升级。
  • 原「中等活动度」在临床实践中被视为「低活动度」。

核心结论

  • 新ASDAS命名法与医生治疗决策一致,支持其更新。
  • 原「中等活动度」状态在临床中常被视为「低活动度」而不升级治疗。

研究设计与样本

  • 纵向回顾性研究,纳入2014年1月至2019年6月首次接受肿瘤坏死因子抑制剂治疗的axSpA患者。
  • 共分析104例患者的304次访视,每次访视后按新ASDAS命名法判定疾病活动度并记录医生治疗决策。

主要发现

  • ASDAS低活动度访视中,医生98.2%选择不升级治疗。
  • ASDAS高活动度访视中,医生33.7%选择升级治疗。
  • ASDAS很高活动度访视中,医生82.8%选择升级治疗。

关键数值与推荐

  • 疾病活动度按新ASDAS命名法分为不活动、低、高和很高活动度。

临床怎么用

  • 临床可依据新ASDAS命名法判断活动度并指导是否升级治疗。
  • ASDAS低活动度通常对应不升级治疗的决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the association between low disease activity according to the new ASDAS nomenclature and the physician therapeutic decisions in patients with axial spondyloarthritis (axSpA). MATERIAL AND METHODS: Longitudinal retrospective study including patients diagnosed with axSpA receiving a tumor necrosis factor-inhibitor between January 2014 and June 2019 as a first treatment. For each visit, disease activity was determined afterwards according to the new ASDAS nomenclature (inactive, low, high and very high activity), and the physician's therapeutic decision was recorded. The association between disease activity and the physician's decision was evaluated through descriptive statistics. RESULTS: A total of 304 visits of 104 patients with axSpA were analyzed. For those visits where a low activity ASDAS score was obtained, the physician's therapeutic decision was no escalation of treatment in 98.2% of cases. However, for those visits with a high or very high disease activity ASDAS score, the physician's therapeutic decision was to escalate treatment in 33.7% and 82.8% of cases respectively. CONCLUSIONS: The state measured by the ASDAS index formerly defined as 'moderated disease activity' is considered in clinical practice as 'low disease activity' because of the physician's choice in these situations to not-escalate the treatment. Our data substantiate the recent updating in ASDAS nomenclature.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Garcia-Magallón B, Castro-Villegas C, Rosello-Pardo R, et al. Is the new ASDAS nomenclature in agreement with therapeutic decision making in patients with axial spondyloarthritis? Semin Arthritis Rheum. 2020. PMID: 32896699. doi:10.1016/j.semarthrit.2020.07.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。